Washington Administrative Code
Title 182 - Health Care Authority
PRESCRIPTION DRUG PROGRAMS
Chapter 182-52 - Prescription drug affordability board
Section 182-52-0035 - Prescription drug affordability board-Review of drug prices
Universal Citation: WA Admin Code 182-52-0035
Current through Register Vol. 24-24, December 15, 2024
(1) By June 30th of each year, using data considered relevant by the board, the board must identify legend drugs and biologics that:
(a) Have been
on the market for at least seven years;
(b) Are dispensed at a retail, specialty, or
mail-order pharmacy; and
(c) Are
not designated by the FDA under
21 U.S.C. Sec.
360bb as a drug solely for the treatment of a
rare disease or condition.
(2) The legend drugs and biologics must meet the following thresholds:
(a) Brand name
drugs and biologic products that must have:
(i) A wholesale acquisition cost of $60,000
or more per year or course of treatment lasting less than 12 months;
or
(ii) A wholesale acquisition
cost increase of 15 percent or more in any 12-month period or for a course of
treatment lasting less than 12 months, or a 50 percent cumulative increase
during any 36-month period.
(b) A biosimilar product with an initial
wholesale acquisition cost that is less than 15 percent lower than the
wholesale acquisition cost of the reference biological product, on the date the
biosimilar becomes available on the market; and
(c) Generic drugs with a wholesale
acquisition cost of $100 or more, for a 30-day supply or course of treatment
less than 30 days, that has an increase in price of 200 percent or more in the
preceding 12 months.
Disclaimer: These regulations may not be the most recent version. Washington may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site. Please check official sources.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
